

Genomic Health, Epic Sciences collaboration, 9/16

September 2016—Genomic Health and Epic Sciences announced an exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test in the U.S. through Genomic Health's commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein in the nucleus of circulating tumor cells—information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer.

Based on the agreement, Genomic Health will have exclusive distribution rights to market and sell the test in the U.S. beginning in early 2017. The test will be performed by Epic Sciences at its CLIA-certified laboratory in San Diego. Physicians will be able to order the test through Genomic Health and view the results through the current physician portal. As part of the agreement, Genomic Health will make an equity investment in Epic Sciences. Further financial terms were not disclosed.

[**Genomic Health**](#), 650-556-9300

[**Epic Sciences**](#), 858-356-6610